NCT05956925

Brief Summary

The investigators' long-term goal is to develop tailored interventions to influence self-management behaviors in young adults with elevated blood pressure (BP). The investigators seek to test an intervention, mobile health (mHealth) to Optimize BP Improvement (MOBILE), that takes advantage of existing applications and our prior work to allow participants to (1) perform self-measured BP monitoring; (2) receive feedback from a cloud-based cardiovascular disease (CVD) detection platform; and (3) receive tailored text messages that encourage engagement in BP reduction behavior. mHealth technology provides an ideal way to deliver healthcare interventions to young adults. Text messaging is especially appealing to college students, more than 91% of whom use smartphones as their main communication device. For this study, the investigators will recruit 42 college students, ages 18 to 29, with elevated BP to participate in formative developmental project and then a 4-week two-armed trial of MOBILE. The aims of this study are: Aim 1. To refine the MOBILE intervention during a formative phase involving 8-10 students. Outcomes will include finalized motivation-level-tailored text messages designed to prompt behavior change and a self-administered motivational scale to be employed in the Aim 2 and Exploratory Aim study. Aim 2. To evaluate the feasibility of implementing the MOBILE intervention in 32 college students with elevated BP. The investigators will operationalize MOBILE feasibility as: (a) acceptability to participants, (b) participation rate, (c) texts delivered and opened, (d) fidelity to daily BP measurement protocol, (e) reported technical problems and challenges, and (f) recruitment and attrition rates. Exploratory Aim. To examine the preliminary impact of the MOBILE intervention on BP reduction (primary outcome) along with sodium intake and hypertension (HTN) knowledge improvement (secondary outcomes) among 32 college students with elevated BP. Hypothesis: The intervention group will have a significantly greater reduction in BP and sodium intake and greater increase in HTN knowledge from baseline to completion, compared to control group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started Dec 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 3, 2020

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

June 22, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 24, 2023

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

August 19, 2024

Completed
Last Updated

August 19, 2024

Status Verified

March 1, 2024

Enrollment Period

7 months

First QC Date

June 22, 2023

Results QC Date

July 27, 2023

Last Update Submit

March 20, 2024

Conditions

Keywords

mhealthhypertensioncollege studentsself-monitoringlifestyle modifications

Outcome Measures

Primary Outcomes (1)

  • BP Level

    BP level (systolic and diastolic BP) was taken using the Withings Wireless BP cuff by the participant in the intervention group.

    Average value from 28 days

Secondary Outcomes (2)

  • Sodium Intake

    Average of Day 1 and Day 28

  • HTN Knowledge

    Average of Day 1 and Day 28

Study Arms (2)

Control

NO INTERVENTION

Following the educational session, the control group participants' BP, ASA24® Dietary Assessment Tool (ASA24; sodium intake), and pre-test knowledge on HTN will be obtained (using Qualitrics). Four weeks later, the participants were scheduled for a follow-up meeting to collect each participant's BP, ASA24, and post-test knowledge on HTN (using Qualitrics).

MOBILE Intervention Group

EXPERIMENTAL

Intervention participants were required to take daily BP, provide their motivation level, and send them to the research assistant to receive the appropriate text messages.

Behavioral: Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.

Interventions

The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.

MOBILE Intervention Group

Eligibility Criteria

Age18 Years - 29 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Aim 1 Formative Phase:
  • Full-time (≥ 12 credits for undergraduate and ≥ 9 credits for graduate) college student at the University of Nevada, Las Vegas (UNLV)
  • Aged 18-29 years.
  • Full-time (≥ 12 credits for undergraduate and ≥ 9 credits for graduate) college student at UNLV
  • Aged 18-29 years
  • Regular access to a mobile smart-phone with unlimited texting
  • Elevated BP (SBP 120-129 mm Hg and diastolic blood pressure \[DBP\] \<80 mm Hg) or undiagnosed HTN stage 1 (SBP 130-139 mm Hg or DBP 80-89 mm Hg). Interested participants who have HTN stage 2 (SBP \>140 mm Hg or DBP \>90 mm Hg) will need clearance from their primary healthcare provider to participate in the study.

You may not qualify if:

  • Taking antihypertensive medication (e.g. angiotensin-converting enzyme \[ACE\] inhibitors, angiotensin II receptor blockers \[ARBs\], calcium channel blockers \[CCBs\], beta-blockers, diuretics, or vasodilators)
  • Currently pregnant, lactating, or planning to become pregnant during the study duration
  • Having diabetes mellitus, hyperlipidemia, or a life-threatening illness or condition associated with HTN.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Nevada Las Vegas

Las Vegas, Nevada, 89154, United States

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Results Point of Contact

Title
Dieu-My Tran (PI)
Organization
University of Nevada, Las Vegas

Study Officials

  • Dieu-My T Tran, PhD, RN

    University of Nevada, Las Vegas

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
No masking was done.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Intervention group vs control group
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 22, 2023

First Posted

July 24, 2023

Study Start

December 3, 2020

Primary Completion

June 30, 2021

Study Completion

June 30, 2022

Last Updated

August 19, 2024

Results First Posted

August 19, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

The pilot study has limited data.

Locations